Daratumumab (Subcutaneously)

DRUG4 trials

Sponsors

Epizyme, Inc., Hellenic Society of Hematology, University Hospital, Martin, Polish Myeloma Consortium

Conditions

Acute Rejection (AR) of Transplanted KidneyKidney TansplantMultiple Myeloma (MM)Primary Plasma Cell LeukemiaRefractory Hematologic MalignancyRelapsed Hematologic Malignancy

Phase 1

A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.

WithdrawnNCT05205252

Epizyme, Inc.Refractory Hematologic Malignancy, Relapsed Hematologic Malignancy

Start: 2021-12-22End: 2023-07-05Updated: 2023-08-15

Phase 2

An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll L

RecruitingNCT06636552

Hellenic Society of HematologyPrimary Plasma Cell Leukemia

Start: 2021-11-19End: 2029-01-05Target: 43Updated: 2024-10-10

Phase 3

A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease

Not yet recruitingNCT07740486

Polish Myeloma ConsortiumMultiple Myeloma (MM)

Start: 2026-09-01End: 2033-04-01Target: 248Updated: 2026-07-31

Unknown Phase

Daratumumab for Late Antibody-Mediated Rejection

RecruitingNCT07081126

University Hospital, MartinAcute Rejection (AR) of Transplanted Kidney, Kidney Tansplant

Start: 2025-07-01End: 2026-12-31Target: 20Updated: 2025-07-23

Related Papers

P1109: TRIAL IN PROGRESS: PHASE 1B/2 TRIAL OF TAZEMETOSTAT IN COMBINATION WITH VARIOUS TREATMENTS IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES

HemaSphere2022-06-01